A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: OTHER: ribociclib|OTHER: aplelicib|OTHER: mono endocrine therapy|OTHER: chemotherapy
Sponsor: Novartis Pharmaceuticals